NEW · Pharmaceuticals
BMY
Bristol-Myers Squibb Co · $134.92B
67.63
+2.38%
Price
251 sessions shownTechnicals
from daily closesRSI · 14 day
62.1
Avg true range · 14d
2.72%
Volatility · 20d annualised
23.6%
Trend · 20d vs 50d
Up
vs 20-day average
5.19%
vs 50-day average
12.61%
vs 200-day average
18.94%
200-day average
56.86
Internals
where it sits, and how hard it is being traded52-week low
42.52
52-week high
68.10
Volume vs its 20-day avg
0.76×
Beta vs the market
0.17
Sitting 98% of the way up its 52-week range (42.52 → 68.10)
Swings
prices it actually turned at — highest or lowest of the surrounding 11 sessionsTurned down · Jun 5
57.82
Turned down · Jun 30
58.88
Turned down · Aug 3
68.10
Turned up · Jun 18
53.44
Turned up · Jul 14
56.78
Turned up · Aug 12
63.00
Fundamentals
P/E
14.21
Fwd P/E
—
P/S
2.68
P/B
5.94
EV/EBITDA
11.03
ROE
46.8%
ROA
10.3%
Gross margin
71.7%
Net margin
—
Debt / equity
2.44
Rev growth
3.1%
EPS growth
5.5%
Earnings
Next report
Oct 29, 2026
EPS expected
1.73
Beat in last 4
4 of 4
2026-06-30reported 2.04 vs 1.60 expected+27.2%
2026-03-31reported 1.58 vs 1.43 expected+10.4%
2025-12-31reported 1.26 vs 1.13 expected+11.9%
2025-09-30reported 1.63 vs 1.52 expected+6.9%
Analyst coverage
35 analysts · as of 2026-08-01Strong buy
6
Buy
8
Hold
19
Sell
2
Strong sell
0
News
stories naming this company, last 21 daysEvery figure here is measured from live market data as of Aug 19, 07:41 PM. Nothing is estimated or filled in — where a figure shows — the source had no value for it, and a section you don’t see had no data at all. This describes what the market has already done. It is not a forecast, and not financial advice.